Physician

Adnan Al-Khalili, MD

According to 2025 Medicare claims, Adnan Al-Khalili, MD (NPI: 1588648786) practices medical oncology in the Toledo, OH market, with the plurality of this provider's patient population coming from Lucas, OH. This provider's primary affiliated billing organization is MERCY HEALTH PHYSICIANS NORTH SPECIALTY CARE LLC (NPI: 1306468418; TIN: 851007420) and primary practice location at 43551-1304. Al-Khalili is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Al-Khalili's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 726 traditional Medicare patients, billed 1,911 HCPCS/CPT codes, and received $134,388 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 4,185 prescription claims across 556 beneficiaries totaling $6,898,126 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 12 claims. Open Payments data shows 6 records totaling $16,198. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $671,664 to $6,898,126. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,155 to $1,622.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	572	1,665	$120,193
2016	757	2,178	$152,632
2017	711	2,356	$166,487
2018	712	2,134	$151,027
2019	701	1,935	$132,962
2020	751	2,083	$140,439
2021	802	2,067	$156,923
2022	716	1,875	$144,624
2023	695	1,905	$138,718
2024	726	1,911	$134,388

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	313	2,319	$671,664
2016	399	3,019	$1,500,003
2017	379	3,220	$2,210,556
2018	393	3,113	$2,902,943
2019	440	3,204	$3,231,699
2020	429	3,279	$4,167,976
2021	463	3,384	$4,290,919
2022	506	3,607	$3,472,550
2023	518	3,588	$4,090,378
2024	556	4,185	$6,898,126

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	38	$16,676
2016	N/R	113	$42,695
2017	11	72	$21,415
2018	N/R	40	$5,639
2019	N/R	47	$6,043
2020	N/R	N/R	N/R
2021	N/R	30	$3,310
2022	N/R	39	$1,421
2023	N/R	12	$572
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	92	98	$130
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	87	87	$120
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	26	27	$102
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	539	1,243	$65
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	142	429	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	129	3,605	$2,020,242
Imbruvica	Ibrutinib	81	2,268	$1,418,421
Lenalidomide	Lenalidomide	52	1,456	$820,628
Xtandi	Enzalutamide	38	1,140	$537,600
Pomalyst	Pomalidomide	20	560	$461,444

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$172	Medtronic, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$16,026	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adnan Al-Khalili, MD?

Tedicare shows public-source Medicare data for Adnan Al-Khalili, MD (NPI 1588648786), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adnan Al-Khalili, MD have ACO affiliation data?

Adnan Al-Khalili, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Adnan Al-Khalili, MD?

Adnan Al-Khalili, MD is linked to MERCY HEALTH PHYSICIANS NORTH SPECIALTY CARE LLC (billing NPI 1306468418) in the available physician profile data.

Does Adnan Al-Khalili, MD have Open Payments data?

Adnan Al-Khalili, MD has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.